Elanco Animal Health Inc ELAN
We take great care to ensure that the data presented and summarized in this overview for Elanco Animal Health Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELAN
View all-
Dodge & Cox San Francisco, CA83.8MShares$1.53 Billion0.84% of portfolio
-
Primecap Management CO Pasadena, CA52.9MShares$964 Million0.65% of portfolio
-
Vanguard Group Inc Valley Forge, PA49.3MShares$898 Million0.02% of portfolio
-
Black Rock Inc. New York, NY26.6MShares$486 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD22.1MShares$404 Million0.04% of portfolio
-
Black Creek Investment Management Inc. Toronto, A620.2MShares$368 Million9.96% of portfolio
-
Dimensional Fund Advisors LP Austin, TX18MShares$328 Million0.08% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il12.1MShares$220 Million0.04% of portfolio
-
Shapiro Capital Management LLC Atlanta, GA10.9MShares$199 Million4.99% of portfolio
-
Ancora Advisors, LLC Cleveland, OH10.6MShares$194 Million4.36% of portfolio
Latest Institutional Activity in ELAN
Top Purchases
Top Sells
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Insider Transactions at ELAN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 21
2024
|
William F Doyle |
BUY
Open market or private purchase
|
Direct |
15,000
+16.42%
|
$240,000
$16.98 P/Share
|
Apr 03
2024
|
Timothy J Bettington |
SELL
Payment of exercise price or tax liability
|
Direct |
23,557
-18.13%
|
$353,355
$15.43 P/Share
|
Apr 01
2024
|
Rajeev A. Modi |
SELL
Payment of exercise price or tax liability
|
Direct |
7,509
-9.72%
|
$112,635
$15.97 P/Share
|
Mar 08
2024
|
Michael J Harrington |
BUY
Open market or private purchase
|
Direct |
3,100
+3.84%
|
$49,600
$16.29 P/Share
|
Mar 08
2024
|
William F Doyle |
BUY
Open market or private purchase
|
Direct |
15,000
+19.65%
|
$240,000
$16.3 P/Share
|
Mar 06
2024
|
R David Hoover |
BUY
Open market or private purchase
|
Indirect |
20,000
+9.76%
|
$320,000
$16.14 P/Share
|
Mar 05
2024
|
Jeffrey N Simmons PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
11,012
-0.81%
|
$165,180
$15.99 P/Share
|
Mar 05
2024
|
Todd S. Young |
BUY
Bona fide gift
|
Indirect |
3,000
+30.0%
|
-
|
Mar 05
2024
|
Todd S. Young |
SELL
Bona fide gift
|
Indirect |
3,000
-0.99%
|
-
|
Mar 05
2024
|
Todd S. Young |
BUY
Bona fide gift
|
Indirect |
37,999
+19.97%
|
-
|
Mar 05
2024
|
Todd S. Young |
SELL
Bona fide gift
|
Direct |
37,999
-27.5%
|
-
|
Mar 01
2024
|
Timothy J Bettington |
BUY
Grant, award, or other acquisition
|
Direct |
21,835
+14.39%
|
-
|
Mar 01
2024
|
Shiv O'Neill GC AND CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,354
-5.39%
|
$21,664
$16.03 P/Share
|
Mar 01
2024
|
Shiv O'Neill GC AND CORP SEC |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+38.3%
|
-
|
Mar 01
2024
|
James M Meer CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,667
-3.2%
|
$26,672
$16.03 P/Share
|
Mar 01
2024
|
James M Meer CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,046
+14.81%
|
-
|
Mar 01
2024
|
Todd S. Young |
SELL
Payment of exercise price or tax liability
|
Direct |
14,000
-9.2%
|
$224,000
$16.03 P/Share
|
Mar 01
2024
|
Todd S. Young |
BUY
Grant, award, or other acquisition
|
Direct |
43,903
+22.39%
|
-
|
Mar 01
2024
|
De Simas Jose Manuel Correia |
SELL
Payment of exercise price or tax liability
|
Direct |
3,642
-6.82%
|
$58,272
$16.03 P/Share
|
Mar 01
2024
|
De Simas Jose Manuel Correia |
BUY
Grant, award, or other acquisition
|
Direct |
10,138
+15.95%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 909K shares |
---|---|
Open market or private purchase | 53.1K shares |
Bona fide gift | 41K shares |
Payment of exercise price or tax liability | 273K shares |
---|---|
Bona fide gift | 41K shares |